BC Cancer - Surrey

13750 96th Avenue
Surrey, BC, V3V 1Z2

Clinical Trial Unit Manager
Nicole Valade
604-319-8067
nicole.valade@bccancer.bc.ca

Breast

CARA: Multicentre Randomized Controlled Trial Of A Carbon-Fibre Adjustable Reusable Accessory For Supine Breast Positioning To Reduce Toxicity In Whole Breast Adjuvant Radiotherapy

Cancer Type
Breast
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
BC Cancer - Surrey
Open Recruiting Date
BC Cancer - Prince George (Centre for the North)
Open Recruiting Date
View on ClinicalTrials.gov

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease

A Phase II Clinical Trial to Evaluate 18F-Fluoroestradiol Positron Emission Tomography / Computerized Tomography (PET/CT) Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

Cancer Type
Breast
Phase III
Recruiting Dates
BC Cancer - Victoria
Open Recruiting Date
BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)
Open Recruiting Date
BC Cancer - Prince George (Centre for the North)
Open Recruiting Date
BC Cancer - Surrey
Open Recruiting Date
BC Cancer - Vancouver
Open Recruiting Date
BC Cancer - Abbotsford
Open Recruiting Date
View on ClinicalTrials.gov

PIK3: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GDC-0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer

FINER: A Double-Blind Placebo-Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Cancer Type
Breast
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
BC Cancer - Surrey
Open Recruiting Date
BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)
View on ClinicalTrials.gov

persevERA: A phase III randomized, double-blind, placeno-controleed, multicentre study evaluating the efficacy and safety of Giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer

Cancer Type
Breast
Phase III
Recruiting Dates
BC Cancer - Victoria
Open Recruiting Date
BC Cancer - Surrey
Open Recruiting Date
View on ClinicalTrials.gov
Back to top